📊 GERN Key Takeaways
Is GERN a Good Investment? Thesis Analysis
Geron is a pre-profitability biopharmaceutical company with severe cash burn of $111M annually against limited revenue of $135.9M, indicating an unsustainable business model. The company is losing $0.61 on every dollar of revenue with negative operating margins of -50.5% and deteriorating free cash flow. While improved net income YoY suggests progress, the fundamental cash burn rate and inability to generate positive operating income present significant going concern risks without successful commercialization.
Why Buy GERN? Key Strengths
- Strong liquidity position with $77.6M cash and 4.66x current ratio providing runway for operations
- YoY improvement in net loss by 52.2% indicating operational progress toward profitability
- Low debt-to-equity ratio of 0.53x with manageable leverage for balance sheet stability
GERN Investment Risks to Consider
- Severe annual cash burn of $111M unsustainable without revenue growth or capital raises
- Negative free cash flow of -$111.7M and -82.2% FCF margin indicates cash depletion trajectory
- Operating losses of -$68.6M with -50.5% operating margin shows core business unable to sustain operations
- Limited revenue base of $135.9M insufficient to cover negative $111M operating cash flow
- Pharmaceutical sector execution risk with uncertain drug commercialization timelines
Key Metrics to Watch
- Quarterly operating cash flow trend and cash runway duration at current burn rate
- Revenue growth rate and gross margins upon drug commercialization
- Quarterly operating loss reduction trajectory toward breakeven
- Capital raise activities and dilution impact on existing shareholders
GERN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.66x current ratio provides a solid financial cushion.
GERN Profitability Ratios
GERN vs Healthcare Sector
How GERON CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GERN Overvalued or Undervalued?
Based on fundamental analysis, GERON CORP shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GERN Balance Sheet & Liquidity
GERN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GERON CORP's revenue has grown significantly by 31% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.32 indicates the company is currently unprofitable.
GERN Growth Metrics (YoY)
GERN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $28.3M | -$16.4M | $-0.03 |
| Q2 2025 | $882.0K | -$16.4M | $-0.02 |
| Q1 2025 | $304.0K | -$19.8M | $-0.03 |
| Q3 2024 | $164.0K | -$26.4M | $-0.04 |
| Q2 2024 | $29.0K | -$38.1M | $-0.09 |
| Q1 2024 | $21.0K | -$38.1M | $-0.07 |
| Q3 2023 | $164.0K | -$28.1M | $-0.08 |
| Q2 2023 | $29.0K | -$28.1M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GERN Capital Allocation
GERN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GERON CORP (CIK: 0000886744)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GERN
What is the AI rating for GERN?
GERON CORP (GERN) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GERN's key strengths?
Claude: Strong liquidity position with $77.6M cash and 4.66x current ratio providing runway for operations. YoY improvement in net loss by 52.2% indicating operational progress toward profitability.
What are the risks of investing in GERN?
Claude: Severe annual cash burn of $111M unsustainable without revenue growth or capital raises. Negative free cash flow of -$111.7M and -82.2% FCF margin indicates cash depletion trajectory.
What is GERN's revenue and growth?
GERON CORP reported revenue of $135.9M.
Does GERN pay dividends?
GERON CORP does not currently pay dividends.
Where can I find GERN SEC filings?
Official SEC filings for GERON CORP (CIK: 0000886744) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GERN's EPS?
GERON CORP has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GERN a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, GERON CORP has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GERN stock overvalued or undervalued?
Valuation metrics for GERN: ROE of -37.0% (sector avg: 15%), net margin of -61.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GERN stock in 2026?
Our dual AI analysis gives GERON CORP a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GERN's free cash flow?
GERON CORP's operating cash flow is $-111.0M, with capital expenditures of $680.0K. FCF margin is -82.2%.
How does GERN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -61.5% (avg: 12%), ROE -37.0% (avg: 15%), current ratio 4.66 (avg: 2).